Atrasentan | CAS:173937-91-2

Chemscene社は、高品質な低分子化合物を提供しているメーカーです。
Chemscene社のAtrasentan(CAS:173937-91-2)をご紹介します。

※本製品は研究用です。研究用以外には使用できません。

Name:Atrasentan; ABT-627; (+)-A 127722; A-147627
Cat. No. :CS-1372
CAS No. :173937-91-2
Formula:C29H38N2O6
M. Wt. : 510.62
Solubility:10 mM in DMSO

Atrasentan is an endothelin receptor antagonist with IC50 of 0.0551 nM for ETA.IC50 & Target: IC50: 0.055 nM (ETA)In Vitro: Atrasentan (ABT-627, 0-50 μM) significantly inhibits LNCaP and C4-2b prostate cancer cell growth. ABT-627 in conbination with Taxotere elicits a significantly greater loss of viable prostate cancer cells relative to either agent alone and shows greater degree of down-regulation of the NF-κB DNA binding activity[2]. Atrasentan profoundly induces several CYPs and drug transporters (e.g. 12-fold induction of CYP3A4 at 50 μM). It is a moderate P-gp inhibitor (IC50 in P388/dx cells=15.1±1.6 μM) and a weak BCRP inhibitor (IC50 in MDCKII-BCRP cells=59.8±11 μM)[3]. In Vivo: Atrasentan (3 mg/kg, p.o.) inhibits the pressor response induced by big endothelin-1 (1 nmol/kg) in pithed rats[1]. Aatrasentan (ABT-627, 10 mg/kg, i.p.) as well as Taxotere alone inhibited the C4-2b tumor growth within the bone environment to some extent in the SCID-hu model[2].

Banerjee S, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 2007 Apr 15;67(8):3818-26. Weiss J, et al. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro. Cancer Chemother Pharmacol. 2011 Oct;68(4):1093-8. Yuyama H, et al. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist. Eur J Pharmacol. 2004 Sep 13;498(1-3):171-7.